These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Islam M, Burke JF, McGowan TA, Zhu Y, Dunn SR, McCue P, Kanalas J, Sharma K. Kidney Int; 2001 Feb; 59(2):498-506. PubMed ID: 11168932 [Abstract] [Full Text] [Related]
10. Blockade of angiotensin II with losartan attenuates transforming growth factor-beta1 inducible gene-h3 (betaig-h3) expression in a model of chronic cyclosporine nephrotoxicity. Sun BK, Li C, Lim SW, Choi BS, Lee SH, Kim IS, Kim YS, Bang BK, Yang CW. Nephron Exp Nephrol; 2005 Feb; 99(1):e9-16. PubMed ID: 15637465 [Abstract] [Full Text] [Related]
12. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy. Yang CW, Ahn HJ, Kim WY, Li C, Jung JY, Yoon SA, Kim YS, Cha JH, Kim J, Bang BK. Transplantation; 2003 Feb 15; 75(3):309-15. PubMed ID: 12589150 [Abstract] [Full Text] [Related]
13. Cyclosporine A up-regulates the expression of TGF-beta1 and its receptors type I and type II in rat mesangial cells. Waiser J, Dell K, Böhler T, Dogu E, Gaedeke J, Budde K, Neumayer HH. Nephrol Dial Transplant; 2002 Sep 15; 17(9):1568-77. PubMed ID: 12198207 [Abstract] [Full Text] [Related]
14. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Gesualdo L, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, Grandaliano G, Schena FP, Ursi M, Cerullo G. Kidney Int; 1999 Aug 15; 56(2):461-70. PubMed ID: 10432384 [Abstract] [Full Text] [Related]
17. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Peters H, Border WA, Noble NA. Kidney Int; 1998 Nov 15; 54(5):1570-80. PubMed ID: 9844133 [Abstract] [Full Text] [Related]
18. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Kidney Int; 2006 Jan 15; 69(1):105-13. PubMed ID: 16374430 [Abstract] [Full Text] [Related]
19. Captopril enhances transforming growth factor (TGF)-beta1 expression in peripheral blood mononuclear cells: a mechanism independent from angiotensin converting enzyme inhibition? A study in cyclosporine-treated kidney-transplanted patients. Di Paolo S, Schena A, Stallone G, Grandaliano G, Soccio M, Cerullo G, Gesualdo L, Paolo Schena F. Transplantation; 2002 Dec 27; 74(12):1710-5. PubMed ID: 12499886 [Abstract] [Full Text] [Related]
20. Transforming growth factor-beta1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Langham RG, Egan MK, Dowling JP, Gilbert RE, Thomson NM. Transplantation; 2001 Dec 15; 72(11):1826-9. PubMed ID: 11740395 [Abstract] [Full Text] [Related] Page: [Next] [New Search]